EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data

Sukanya Siriyotha iD, Thitiya Lukkunaprasit iD, Panu Looareesuwan iD, Patratorn Kunakorntham iD, Thunyarat Anothaisintawee iD, Hataikarn Nimitphong iD, Gareth J McKay iD, John Attia iD, Ammarin Thakkinstian iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Sukanya Siriyotha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To estimate individual treatment effects (ITEs) of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) on lowering the risk of developing chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) and to identify those most probable to benefit from treatment.

Methods

This study followed a T2D cohort from Ramathibodi Hospital, Thailand, from 2015 to 2022. A counterfactual model was constructed to predict factual and counterfactual risks of CKD if patients did/did not receive SGLT2is. ITEs were estimated by subtracting the factual risk from the counterfactual risk of CKD.

Results

There were 1619 and 15 879 patients included in the SGLT2i and non‐SGLT2i groups, respectively. The estimated ITEs varied from −1.19% to −17.51% with a median of −4.49%, that is, 50% of patients had a 4.49% or greater lower CKD risk if they received an SGLT2i. Patients who gained the greatest benefit from SGLT2is were more probable to be male, aged at least 60 years, with a history of diabetes duration of at least 3 months, hypertension, peripheral arterial disease, diabetic retinopathy and low high‐density lipoprotein cholesterol.

Conclusions

Our prediction model provides individualized information that helps target T2D patients who may benefit more from SGLT2is. This could help clinical decision making and implementation of personalized medicine in clinical practice, especially in resource‐limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansMaleFemaleMiddle AgedAgedThailandTreatment OutcomeDiabetic NephropathiesRisk FactorsCohort StudiesRisk Assessment

Stichwörter der Autor:innen

chronic kidney diseasecounterfactual prediction modeldiabetic kidney diseasesodium‐glucose co‐transporter‐2 inhibitorstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pharmacy Administration, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
  • Department of Information Technology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Family Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

ORCID-Profile: Sukanya Siriyotha, Thitiya Lukkunaprasit, Panu Looareesuwan, Patratorn Kunakorntham, Thunyarat Anothaisintawee, Hataikarn Nimitphong, Gareth J McKay, John Attia, Ammarin Thakkinstian

Förderung

  • National Research Council of Thailand

Zitieren

APA

Siriyotha, S., Lukkunaprasit, T., Looareesuwan, P., Kunakorntham, P., Anothaisintawee, T., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2024). Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15793

Vancouver

Siriyotha S, Lukkunaprasit T, Looareesuwan P, Kunakorntham P, Anothaisintawee T, Nimitphong H, et al. Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15793

BibTeX
@article{Siriyotha2024,
  author = {Siriyotha, Sukanya and Lukkunaprasit, Thitiya and Looareesuwan, Panu and Kunakorntham, Patratorn and Anothaisintawee, Thunyarat and Nimitphong, Hataikarn and McKay, Gareth J and Attia, John and Thakkinstian, Ammarin},
  title = {Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15793}
}
Kostenlos starten →